What's hot
View all perspectives
What's Hot
Psoriatic Arthritis Panel: EULAR 2025
Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Spondyloarthritis Panel: Eular 2025
Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.
Watch video →
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
Watch video →
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.
Watch video →
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
Watch video →
Hidradenitis Suppurativa: What Lies Beneath?
Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read more →
Social determinants of health (SDH), such as socioeconomic status and educational background are factors that are increasingly recognised as critical contributors to health outcomes in chronic diseases. Understanding how certain factors impact different RMDs is important, and new research into this for both systemic lupus erythematosus (SLE) and inflammatory arthritis was presented at the 2025 annual EULAR congress in Barcelona.
Nelly ZIADE 🍀 Nellziade
6 months ago
Diagnostic delay in #SpA
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay was 6.6 years
🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA
🔹️Associated with type of initial symptoms (shorter in peripheral)
POS0909 #EULAR2025
@rheumnow https://t.co/3BMYFxbKiq
Adela Castro AdelaCastro222
6 months ago
LDCT to assess disease progression in early axSpA:
-Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+)
- LDCT at baseline and 2 years apart.
-Overall 22% pt with net disease progression.
-Spine progression most frequent on thoracic spine.
-Good reliability in assessing https://t.co/M2jkDusD41
Jiha Lee JihaRheum
6 months ago
🎯 Early MTX hits the mark — but only in ACPA-negative.
In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years:
➖ Less RA
➖ Better function
❌ No benefit in ACPA+
Abstract#OP0324 @RheumNow #EULAR2025
Janet Pope Janetbirdope
6 months ago
#ANCA #vasculitis is not created equally
REVEAL cohort 588 ANCA
Initial & 12 months #BVAS (activity index)
mean ⬇️BVAS over 1 yr in all groups
#GPA #MPA #eGPA
5yr survival not = over time
⬆️survival in eGPA & GPA vs MPA
#POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
Md Yuzaiful Md Yusof Yuz6Yusof
6 months ago
#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR
David Liew drdavidliew
6 months ago
Is RA just one disease?
No, & increasingly more efforts to subgroup RA on diff levels
Simple approach - derived phenotypes map (independent of ACPA):
- to broad histopath
- to MTX response
Omics is good, but still need to do the simple stuff better!
#EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso
Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
Antoni Chan MD (Prof) synovialjoints
6 months 1 week ago
In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference (β −0.36, 95% CI −0.73 to 0.01) and affective distress (β −0.40, 95% CI −0.84 to 0.003) vs standard of care (SOC). 43% completed full program. NPS 5.8. https://t.co/T6i9jkjcoU
Antoni Chan MD (Prof) synovialjoints
6 months 1 week ago
In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR 1.20), depression (OR 1.22). D2T group had higher CRP (55.7 mg/L), BMI (31.1), and more EAMs (IBD, psoriasis, uveitis). Female predominance (56.9%)Abstract https://t.co/EHCt5wq4ot
Md Yuzaiful Md Yusof Yuz6Yusof
6 months 1 week ago
#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow https://t.co/WoVFolrmPA
Md Yuzaiful Md Yusof Yuz6Yusof
6 months 1 week ago
#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality:
- Lower income & education,
- No partner
- On sick leave/disability benefits
@RheumNow https://t.co/hgEfJzoqNg
Md Yuzaiful Md Yusof Yuz6Yusof
6 months 1 week ago
#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984
Poster Hall